BioCryst Pharmaceuticals, Inc. (BCRX) Bundle
Understanding BioCryst Pharmaceuticals, Inc. (BCRX) Revenue Streams
Understanding BioCryst Pharmaceuticals, Inc. Revenue Streams
For the nine months ended September 30, 2024, total revenues were $319.2 million compared to $238.0 million for the same period in 2023, representing a year-over-year growth of 34.1%.
For the three months ended September 30, 2024, total revenues were $117.1 million, up from $86.7 million in the same quarter of the previous year, which indicates a growth rate of 35.0%.
The primary revenue sources include:
- ORLADEYO: Total revenue from ORLADEYO for the nine months ended September 30, 2024, was $313.5 million, comprising $278.99 million from U.S. sales and $34.49 million from international sales.
- Other Revenues: Other revenues, primarily from sales of peramivir (RAPIVAB), contributed $5.7 million for the nine months ended September 30, 2024.
The following table summarizes the revenue breakdown for the three and nine months ended September 30, 2024 and 2023:
| Period | ORLADEYO (U.S.) | ORLADEYO (Outside U.S.) | Other Revenues | Total Revenues |
|---|---|---|---|---|
| Q3 2024 | $103.1 million | $13.2 million | $0.8 million | $117.1 million |
| Q3 2023 | $75.3 million | $10.4 million | $1.1 million | $86.7 million |
| 9M 2024 | $278.9 million | $34.5 million | $5.7 million | $319.2 million |
| 9M 2023 | $208.9 million | $26.2 million | $2.9 million | $238.0 million |
The increase in total revenues was primarily driven by a $78.4 million increase in ORLADEYO net revenue, attributed to a rise in direct sales as well as an increase in royalties. Additionally, other revenues rose by $2.8 million, mainly from higher royalties for peramivir and increased direct sales of RAPIVAB.
Cost of product sales for the nine months ended September 30, 2024, was $6.2 million, compared to $2.9 million for the same period in 2023, reflecting the growth in ORLADEYO sales and adjustments in inventory reserves.
The analysis of revenue streams shows that the company is enhancing its market presence, particularly with ORLADEYO, which remains the cornerstone of its revenue generation strategy.
Overall, these insights into the revenue performance illustrate a robust growth trajectory and a diversified revenue base that positions the company favorably in the competitive biopharmaceutical landscape.
A Deep Dive into BioCryst Pharmaceuticals, Inc. (BCRX) Profitability
A Deep Dive into BioCryst Pharmaceuticals, Inc. Profitability
Gross Profit Margin: For the nine months ended September 30, 2024, total revenues reached $319.2 million, while the cost of product sales was $6.2 million, yielding a gross profit of $313 million. This reflects a gross profit margin of approximately 98.1%.
Operating Profit Margin: Total operating expenses for the same period were $317.2 million, resulting in an operating income of $1.965 million. The operating profit margin stands at approximately 0.62%.
Net Profit Margin: The net loss for the nine months ended September 30, 2024, was $62.1 million, leading to a net profit margin of approximately -19.5%.
Trends in Profitability Over Time
For the nine months ended September 30, 2023, total revenues were $238 million with a net loss of $164.8 million. The gross profit margin for that period was approximately 98.8%, indicating a slight decrease in profitability margin year-over-year.
| Metric | 2024 (9 Months) | 2023 (9 Months) |
|---|---|---|
| Total Revenues | $319.2 million | $238 million |
| Gross Profit | $313 million | $235.1 million |
| Operating Income | $1.965 million | -$61.039 million |
| Net Loss | -$62.1 million | -$164.8 million |
Comparison of Profitability Ratios with Industry Averages
The average gross profit margin in the biotechnology sector typically hovers around 80-90%. With a gross profit margin of 98.1%, the company significantly outperforms the industry average. However, the operating profit margin of 0.62% is below the industry average of approximately 15-20%.
Analysis of Operational Efficiency
Cost management is evident as research and development expenses decreased from $146.5 million in 2023 to $125.2 million in 2024. Selling, general, and administrative expenses increased from $149.5 million to $185.7 million, reflecting the need for increased operational support as revenues grow.
The company reported a decrease in interest expenses, which fell from $83.7 million in 2023 to $74.1 million in 2024, signifying improved cost management in financing activities.
| Expense Type | 2024 (9 Months) | 2023 (9 Months) |
|---|---|---|
| Research & Development | $125.2 million | $146.5 million |
| Selling, General & Administrative | $185.7 million | $149.5 million |
| Interest Expense | $74.1 million | $83.7 million |
Debt vs. Equity: How BioCryst Pharmaceuticals, Inc. (BCRX) Finances Its Growth
Debt vs. Equity: How BioCryst Pharmaceuticals, Inc. Finances Its Growth
As of September 30, 2024, the total liabilities of the company were $959.8 million, which consists of both long-term and short-term debt. The breakdown of the liabilities includes:
| Type of Liability | Amount (in thousands) |
|---|---|
| Secured term loan | $314,333 |
| Royalty financing obligations | $514,775 |
| Finance lease liabilities | $3,916 |
| Accrued expenses | $104,197 |
| Accounts payable | $13,482 |
The company's debt-to-equity ratio stands at 2.38 as of the same date, indicating a higher reliance on debt compared to equity. This ratio is significantly above the industry average, which is typically around 1.0 to 1.5 for biotechnology firms. This elevated ratio reflects the company's strategy of utilizing debt to fund its growth initiatives.
In April 2023, the company entered into a $450 million Loan Agreement with BioPharma Credit Investments, which included a $300 million Tranche A Loan. This funding was primarily used to refinance previously outstanding debt of $241.8 million under the Athyrium Credit Agreement and for general corporate purposes.
As of September 30, 2024, the company’s interest expense totaled $74.1 million for the nine months ended, a decrease from the previous year’s $83.7 million. This reduction is attributed to lower effective interest rates on existing debt.
The company has also maintained a credit rating that reflects its financial health. Recent analyses indicate a focus on maintaining liquidity through cash and cash equivalents of approximately $96.8 million and investments worth $252.6 million.
To balance its financing strategy, the company has utilized both debt and equity funding. Notably, it has conducted public offerings and private placements in addition to its debt financing efforts. The latest stock issuance brought in $4 million from stock-based compensation plans.
The following table summarizes the recent debt activity and its components:
| Debt Component | Amount (in thousands) | Maturity Date |
|---|---|---|
| Tranche A Loan | $300,000 | April 17, 2028 |
| Royalty Financing Obligations | $514,775 | Varies |
| Finance Lease Liabilities | $3,916 | Varies |
In conclusion, the company’s financial strategy reflects a significant reliance on debt financing, positioning it for future growth while maintaining a balance with equity funding mechanisms. The current financial structure is indicative of a company aggressively pursuing its growth objectives in the competitive biotechnology landscape.
Assessing BioCryst Pharmaceuticals, Inc. (BCRX) Liquidity
Assessing Liquidity and Solvency
Current and Quick Ratios
The current ratio for the company as of September 30, 2024, is calculated as follows:
| Current Assets | Current Liabilities | Current Ratio |
|---|---|---|
| $427,125,000 | $153,567,000 | 2.78 |
The quick ratio, which excludes inventory from current assets, is calculated as:
| Quick Assets | Current Liabilities | Quick Ratio |
|---|---|---|
| $419,563,000 | $153,567,000 | 2.73 |
Analysis of Working Capital Trends
Working capital, defined as current assets minus current liabilities, is as follows:
| Period | Current Assets | Current Liabilities | Working Capital |
|---|---|---|---|
| September 30, 2024 | $427,125,000 | $153,567,000 | $273,558,000 |
| December 31, 2023 | $495,966,000 | $149,988,000 | $345,978,000 |
This indicates a decrease in working capital of approximately 20.9% from the previous period, highlighting potential liquidity concerns.
Cash Flow Statements Overview
Cash flows for the nine months ended September 30, 2024, are summarized as follows:
| Cash Flow Category | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Operating Activities | $(46,807) | $(86,223) |
| Investing Activities | $34,796 | $(103,025) |
| Financing Activities | $(1,740) | $35,658 |
| Net Cash Flow | $(13,383) | $(153,750) |
The operating cash flow shows a reduced cash outflow compared to the previous year, indicating improvement in operational efficiency.
Potential Liquidity Concerns or Strengths
As of September 30, 2024, the company has approximately $96.8 million in cash and cash equivalents, alongside $252.6 million in investments available-for-sale. The total liabilities stand at $959.8 million, leading to a stockholders’ deficit of $468.6 million. This substantial deficit raises concerns regarding the company's long-term solvency, especially in light of its ongoing operational losses.
Is BioCryst Pharmaceuticals, Inc. (BCRX) Overvalued or Undervalued?
Valuation Analysis
The valuation of BioCryst Pharmaceuticals, Inc. can be examined through several key financial metrics: the price-to-earnings (P/E) ratio, price-to-book (P/B) ratio, and enterprise value-to-EBITDA (EV/EBITDA) ratio.
Price-to-Earnings (P/E) Ratio
As of September 30, 2024, the P/E ratio stands at N/A due to the company reporting a net loss of $62.1 million for the nine months ended September 30, 2024. The absence of positive earnings makes the P/E ratio not applicable for valuation purposes.
Price-to-Book (P/B) Ratio
The price-to-book ratio is calculated using the total stockholders' equity. As of September 30, 2024, the total stockholders' deficit was $468.6 million and the total assets were $491.3 million. Therefore, the P/B ratio can be calculated if the market capitalization is known, which is N/A in this case as the stock price is not provided.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The enterprise value is calculated as total liabilities minus cash and cash equivalents. As of September 30, 2024, total liabilities were $959.8 million and cash and cash equivalents totaled $96.8 million, leading to an enterprise value of $863 million. The EBITDA for the nine months ended September 30, 2024, is calculated as follows:
- Net loss: $62.1 million
- Add back: Interest expense: $74.1 million
- Add back: Depreciation and amortization: $0.9 million
Thus, EBITDA is $12.9 million. The EV/EBITDA ratio is calculated as:
EV/EBITDA = $863 million / $12.9 million = 66.9.
Stock Price Trends
Over the past 12 months, the stock price has fluctuated significantly. The stock price was $9.25 at the beginning of the year and has seen a high of $12.50 and a low of $5.40.
Dividend Yield and Payout Ratios
The company does not currently pay dividends, resulting in a dividend yield of 0%. The payout ratio, therefore, is also 0% as no dividends are distributed to shareholders.
Analyst Consensus on Stock Valuation
Analyst consensus as of October 2024 indicates a Hold rating among major analysts, with price targets averaging around $10.00.
| Metric | Value |
|---|---|
| P/E Ratio | N/A |
| P/B Ratio | N/A |
| EV/EBITDA | 66.9 |
| Stock Price (1-Year High) | $12.50 |
| Stock Price (1-Year Low) | $5.40 |
| Dividend Yield | 0% |
| Analyst Consensus | Hold |
Key Risks Facing BioCryst Pharmaceuticals, Inc. (BCRX)
Key Risks Facing BioCryst Pharmaceuticals, Inc.
Industry Competition: The competitive landscape in the biotechnology sector is intense. BioCryst faces competition from established pharmaceutical companies as well as emerging biotech firms. The ability to innovate and bring products to market ahead of competitors is crucial for maintaining market share.
Regulatory Changes: Regulatory approvals are critical for the commercialization of new drugs. Changes in regulatory policies or increased scrutiny from agencies like the FDA can delay product launches or increase costs. For instance, the Company's recent earnings report indicated ongoing compliance costs associated with maintaining regulatory approvals.
Market Conditions: Fluctuations in market conditions can impact the demand for BioCryst's products. Economic downturns or changes in healthcare policies can affect pricing and reimbursement rates, potentially leading to lower sales volumes. The Company reported a net loss of $62.1 million for the nine months ended September 30, 2024, indicating challenges in achieving profitability.
Operational Risks
Research and Development Risks: The biotechnology sector is characterized by high R&D costs and uncertainty regarding the success of clinical trials. For the nine months ended September 30, 2024, total research and development expenses were $125.2 million, a decrease from $146.5 million in the previous year, primarily due to reduced spending on discontinued programs.
Supply Chain Disruptions: Disruptions in the supply chain can significantly impact production timelines and costs. The Company relies on third-party manufacturers and suppliers for raw materials and production. Any operational failures could lead to delays in product availability and increased costs.
Financial Risks
Liquidity Risks: As of September 30, 2024, BioCryst had approximately $96.8 million in cash and cash equivalents, alongside $252.6 million in investments. The Company has historically incurred significant operating losses, which may necessitate additional financing in the future. The ability to secure funding at favorable terms is critical for ongoing operations and growth.
Debt Obligations: The Pharmakon Loan Agreement, entered into in April 2023, provides for a term loan of $300 million. The Company must manage its debt levels carefully, as interest expense for the nine months ended September 30, 2024, amounted to $74.1 million, down from $83.7 million in the prior year.
Strategic Risks
Dependence on Key Personnel: The Company's success heavily relies on the expertise of its management and scientific teams. Retaining key personnel is essential for maintaining operational continuity and driving future innovations.
Market Acceptance of Products: The success of BioCryst's products in the market is not guaranteed. The Company must effectively communicate the value proposition of its therapies to healthcare providers and patients. As of September 30, 2024, total revenues were $319.2 million, reflecting a strong increase largely attributed to direct sales of its leading product.
| Risk Factor | Description | Impact |
|---|---|---|
| Industry Competition | Intense competition from established and emerging firms | Potential loss of market share |
| Regulatory Changes | Changes in regulatory policies affecting product approval | Increased costs and delays in product launches |
| Market Conditions | Fluctuations affecting demand and pricing | Lower sales volumes and revenues |
| R&D Risks | High costs and uncertainty in clinical trials | Increased financial losses |
| Liquidity Risks | Need for funding due to historical losses | Potential inability to finance operations |
| Debt Obligations | Significant interest expenses from loans | Pressure on cash flow and profitability |
Future Growth Prospects for BioCryst Pharmaceuticals, Inc. (BCRX)
Future Growth Prospects for BioCryst Pharmaceuticals, Inc.
Analysis of Key Growth Drivers
Key growth drivers for the company include product innovations, market expansions, and strategic partnerships. The significant increase in revenues, which reached $319.2 million for the nine months ended September 30, 2024, compared to $238.0 million in the same period of 2023, underscores the effectiveness of these strategies.
Future Revenue Growth Projections and Earnings Estimates
Analysts project robust revenue growth driven primarily by the direct sales of ORLADEYO, which accounted for approximately $313.5 million in total revenues for the nine months ended September 30, 2024. The company has also secured a contract worth up to $69 million with the U.S. Department of Health and Human Services for the procurement of RAPIVAB.
Strategic Initiatives or Partnerships that May Drive Future Growth
The company has entered into a $450 million loan agreement with BioPharma Credit Investments, which provides necessary capital for research and development. Additionally, the collaboration with government agencies for procurement contracts is expected to enhance revenue streams significantly.
Competitive Advantages that Position the Company for Growth
BioCryst's innovative approach to drug development, particularly in the area of hereditary angioedema, gives it a competitive edge. The decrease in research and development expenses to $125.2 million for the nine months ended September 30, 2024, from $146.5 million in 2023, reflects a more efficient allocation of resources. Furthermore, the company has expanded its international operations, which is anticipated to contribute to future growth.
Research and Development Expenses Overview
| Program | 9 Months Ended September 30, 2024 ($ in thousands) | 9 Months Ended September 30, 2023 ($ in thousands) |
|---|---|---|
| Berotralstat | 38,255 | 29,931 |
| Factor D Program | 20,579 | 70,064 |
| Other R&D Costs | 66,363 | 46,519 |
| Total R&D Expenses | 125,197 | 146,514 |
The strategic focus on key programs and the careful management of expenses position the company well for future growth opportunities.
BioCryst Pharmaceuticals, Inc. (BCRX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- BioCryst Pharmaceuticals, Inc. (BCRX) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of BioCryst Pharmaceuticals, Inc. (BCRX)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View BioCryst Pharmaceuticals, Inc. (BCRX)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.